Tolcapone Composition for Rett Syndrome Neuronal Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett syndrome, which is characterized by neuronal atrophy and oxidative stress, do not effectively address these symptoms and often have limitations in mechanism of action.
Innovation Solution
The use of tolcapone, a COMT inhibitor, is repurposed for Rett syndrome treatment, leveraging its ability to penetrate the blood-brain barrier and activate neuronal maturation by targeting AKR1B1, an enzyme involved in the arachidonic acid signaling cascade to reduce oxidative stress, potentially combined with calcipotriene or idoxuridine for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug treatments are used for Rett syndrome, then some symptomatic relief may be achieved, but they fail to effectively address neuronal atrophy and oxidative stress
Solution Approach 1:
The patent changes the mechanism of action parameter by switching from traditional COMT inhibition to dual action on AKR1B1 inhibition and BDNF induction, fundamentally altering how the drug treats Rett syndrome pathology
Solution Approach 2:
Tolcapone is repurposed to perform multiple functions: inhibiting AKR1B1 enzyme, inducing BDNF expression, and reducing oxidative stress, making it a multi-functional treatment for Rett syndrome
2Reliability
If gene therapy approaches are used to reactivate MECP2, then disease reversal can be achieved, but the treatment is not accessible or appropriate for all patients
Solution Approach 1:
The patent employs a small molecule drug (tolcapone) that is orally administrable and relatively inexpensive compared to gene therapy, making it accessible to broader patient populations while achieving therapeutic effects
Solution Approach 2:
Tolcapone acts as a chemical intermediary that indirectly achieves disease reversal by modulating AKR1B1 and BDNF pathways, providing an alternative to direct gene reactivation approaches
3Adaptability or versatility
If tolcapone is used to inhibit COMT enzyme, then Parkinson disease symptoms are treated, but Rett syndrome specific pathology involving AKR1B1 and oxidative stress is not addressed
Solution Approach 1:
The patent extends tolcapone's functionality beyond COMT inhibition to include AKR1B1 inhibition and BDNF induction, enabling it to treat Rett syndrome specifically while maintaining its Parkinson disease therapeutic value
Solution Approach 2:
The patent changes the target parameter from COMT enzyme to AKR1B1 enzyme and BDNF expression levels, adapting tolcapone's mechanism to address Rett syndrome pathology specifically
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Tolcapone, alone or in combination with other drugs, promotes neuronal maturation and reduces oxidative stress, effectively counteracting neuronal atrophy in Rett syndrome models, offering a novel mechanism of action beyond traditional COMT inhibition.
Implementation Method 1
leveraging its ability to penetrate the blood-brain barrier
Implementation Method 2
activate neuronal maturation by targeting AKR1B1, an enzyme involved in the arachidonic acid signaling cascade to reduce oxidative stress
Implementation Method 3
activate neuronal maturation by targeting AKR1B1, an enzyme involved in the arachidonic acid signaling cascade
Data Source
Figure 1
Figure 2A~3B
Figure 3C~4B
AI summary
The present invention concerns a composition for use for, or for the treatment of, Rett syndrome, which proposes a repositioning of a selective and reversible catechol-O-methyltransferase (COMT) inhibitor.